

Drug Monograph

Drug Name: **Xofluza® (baloxavir marboxil) tablet**
 Drug Class: **Anti-Infectives: Antiviral, Flu Virus**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Xofluza is now available in an 80 mg tablet. The new strength joins the 40 mg tablet and the 40 mg/20 mL oral suspension.

Manufacturer: Distributed by: Genentech USA, Inc., South San Francisco, CA 94080.

Indications: Xofluza is indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are:

- otherwise healthy, or
- at risk of developing influenza-related complications.

Xofluza is also indicated for post-exposure prophylaxis of influenza in patients 12 years of age and older following contact with an individual who has influenza.

Costs: \$154.50 per course of one (1) 80 mg tablet. Wholesale Acquisition Cost

Summary of Findings: The MO HealthNet Division recommends prior authorization status for this product.

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: April Ash, PharmD
 Date: September 1, 2021